PCNAT 1
Alternative Names: PCNAT-1Latest Information Update: 02 Aug 2024
At a glance
- Originator Anda Biopharmaceutical Development
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pancreatic cancer
Most Recent Events
- 02 Aug 2024 ANDA Bioparmaceuticals announces intention to submit IND application to US FDA and Chinese NMPA for Pancreatic cancer (ANDA Biopharmaceuticals website, August 2024)
- 31 May 2024 Efficacy, pharmacodynamics and adverse event data from a phase I trial in pancreatic cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 Mar 2022 PCNAT 1 receives Orphan Drug status for Pancreatic cancer in USA (ANDA BioPharmaceuticals website)